Evidence map›Paper›PMID 31414050›Full record

ArticleScience advances2019

Application of hydroxyapatite nanoparticles in tumor-associated bone segmental defect.

Kun Zhang, Yong Zhou, Cong Xiao, Wanlu Zhao, Hongfeng Wu, Jiaoqing Tang, Zhongtao Li, Sen Yu, Xiangfeng Li, Li Min and 8 more

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 257 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Application of mass cytometry in the immune microenvironment of breast cancer.Medical oncology (Northwood, London, England) · 2025
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Additive manufacturing in nano drug delivery systems.Pharmaceutical science advances · 2024
    Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Kun ZhangNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610064, China.ORCID 0000-0003-3475-7127
Yong ZhouDepartment of Orthopaedic Surgery, West China Hospital of Sichuan University, Chengdu 610041, China.ORCID 0000-0002-1078-6137
Cong XiaoDepartment of Orthopaedic Surgery, West China Hospital of Sichuan University, Chengdu 610041, China.
Wanlu ZhaoNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610064, China.
Hongfeng WuNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610064, China.
Jiaoqing TangDepartment of Dermatology, West China Hospital of Sichuan University, Chengdu 610041, China.
Zhongtao LiDepartment of Dermatology, West China Hospital of Sichuan University, Chengdu 610041, China.
Sen YuShaanxi Key Laboratory of Biomedical Metal Materials, Northwest Institute for Non-ferrous Metal Research, Xi'an 710016, China.
Xiangfeng LiNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610064, China.
Li MinDepartment of Orthopaedic Surgery, West China Hospital of Sichuan University, Chengdu 610041, China.
Zhentao YuShaanxi Key Laboratory of Biomedical Metal Materials, Northwest Institute for Non-ferrous Metal Research, Xi'an 710016, China.
Gang WangNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610064, China.
Lin WangDepartment of Dermatology, West China Hospital of Sichuan University, Chengdu 610041, China.
Kai ZhangNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610064, China.
Xiao YangNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610064, China.ORCID 0000-0001-7248-8218
Xiangdong ZhuNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610064, China.ORCID 0000-0002-3818-7419
Chongqi TuDepartment of Orthopaedic Surgery, West China Hospital of Sichuan University, Chengdu 610041, China.ORCID 0000-0002-1781-4073
Xingdong ZhangNational Engineering Research Center for Biomaterials, Sichuan University, Chengdu, 610064, China.
Sichuan University · CNNorthwest Institute For Non-Ferrous Metal Research · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydroxyapatite (HA) has been widely applied in bone repair because of its superior biocompatibility. Recently, a proliferation-suppressive effect of HA nanoparticles (n-HA) against various cancer cells was reported. This study was aimed at assessing the translational value of n-HA both as a bone-regenerating material and as an antitumor agent. Inhibition of tumor growth, prevention of metastasis, and enhancement of the survival rate of tumor-bearing rabbits treated with n-HA were demonstrated. Activated mitochondrial-dependent apoptosis in vivo was confirmed, and we observed that a stimulated immune response was involved in the n-HA-induced antitumor effect. A porous titanium scaffold loaded with n-HA was fabricated and implanted into a critical-sized segmental bone defect in a rabbit tumor model. The n-HA-releasing scaffold not only showed a prominent effect in suppressing tumor growth and osteolytic lesion but also promoted bone regeneration. These findings provide a rationale for using n-HA in tumor-associated bone segmental defects.

Indexed as

Bone RegenerationDurapatiteAnimalsDisease Models, AnimalMaleNanoparticlesNeoplasmsPorosityRabbitsTissue ScaffoldsTitaniumDurapatiteTitanium

Identifiers

PMID31414050
PMCPMC6677551
OpenAlexW2966791866

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.